A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-ThalassemiaMaria Domenica Cappellini, Antonio Piga, Vip Viprakasit et al.|New England Journal of Medicine|2020Cited by 320
Hepatocellular carcinoma in thalassaemia: an update of the Italian RegistryCaterina Borgna‐Pignatti, Stefano Volpato, Paolo Cianciulli et al.|British Journal of Haematology|2014Cited by 83
The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) TransfusionsMaria Domenica Cappellini, Antonio Piga, Vip Viprakasit et al.|Blood|2018Cited by 14
Thalassaemia is paradoxically associated with a reduced risk of in‐hospital complications and mortality in COVID‐19: Data from an international registryIbrahim El‐Battrawy, İbrahim Akın, Filomena Longo et al.|Journal of Cellular and Molecular Medicine|2022Cited by 10
Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in β-Thalassemia with Luspatercept: Longitudinal Results of the Believe TrialAlì Taher, Maria Domenica Cappellini, Vip Viprakasit et al.|Blood|2020Cited by 8